Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway

Rowley, 1980, Ph1-positive leukaemia, including chronic myelogenous leukaemia, Clin Haematol, 9, 55, 10.1016/S0308-2261(21)00164-8

Groffen, 1984, Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22, Cell, 36, 93, 10.1016/0092-8674(84)90077-1

Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science, 293, 876, 10.1126/science.1062538

Okabe, 2014, Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation, Cancer Biol Ther, 15, 207, 10.4161/cbt.26725

Sun, 2015, NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation, Onco Targets Ther, 8, 269

Xu, 2016, Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin, J Clin Invest, 126, 3526, 10.1172/JCI86120

Morran, 2014, Targeting mTOR dependency in pancreatic cancer, Gut, 63, 1481, 10.1136/gutjnl-2013-306202

Mohi, 2004, Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs, Proc Natl Acad Sci USA, 101, 3130, 10.1073/pnas.0400063101

Parmar, 2005, Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells, Blood, 106, 2436, 10.1182/blood-2004-10-4003

Hirase, 2009, Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor, Leuk Res, 33, 450, 10.1016/j.leukres.2008.07.023

Batista, 2011, Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors, Exp Hematol, 39, 457, 10.1016/j.exphem.2011.01.005

Li, 2012, Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia, Oncol Rep, 27, 461

LoPiccolo, 2008, Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations, Drug Resist Updat, 11, 32, 10.1016/j.drup.2007.11.003

Guo, 2019, Effects of neddylation and mTOR inhibition in acute myelogenous leukemia, Transl Oncol, 12, 602, 10.1016/j.tranon.2019.01.001

Ly, 2003, Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin, Cancer Res, 63, 5716

Xin, 2017, Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines, Drug Des Devel Ther, 11, 1115, 10.2147/DDDT.S132092

Li, 2014, Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway, Tumour Biol, 35, 6467, 10.1007/s13277-014-1820-5

Harada, 2001, p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD, Proc Natl Acad Sci USA, 98, 9666, 10.1073/pnas.171301998

Xie, 2016, Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes, Oncol Lett, 12, 375, 10.3892/ol.2016.4636

Vicary, 2016, Targeting the mammalian target of rapamycin in lung cancer, Am J Med Sci, 352, 507, 10.1016/j.amjms.2016.08.014

Kurgan, 2017, Inhibition of human lung cancer cell proliferation and survival by post-exercise serum is associated with the inhibition of Akt, mTOR, p70 S6K, and Erk1/2, Cancers (Basel), 9, E46, 10.3390/cancers9050046

Wiesweg, 2018, Phosphorylation of p70 ribosomal protein S6 kinase β-1 is an independent prognostic parameter in metastatic colorectal cancer, Clin Colorectal Cancer, 17, e331, 10.1016/j.clcc.2018.02.003

Morjani, 1992, Intranuclear concentration measurements of doxorubicin in living leucocytes from patients treated for a lympho-proliferative disorder, Leuk Res, 16, 647, 10.1016/0145-2126(92)90015-Y

Speth, 1989, In vivo and in vitro pharmacokinetic differences between four structurally closely related anthracyclines in hematopoietic cell subtypes in humans, Drug Metab Dispos, 17, 98

Skorkina, 2018, Study of the properties of doxorubicin-resistant cells affected by acute leucosis, J Bioenerg Biomembr, 50, 53, 10.1007/s10863-017-9738-4

Chekin, 2019, Graphene-modified electrodes for sensing doxorubicin hydrochloride in human plasma, Anal Bioanal Chem, 411, 1509, 10.1007/s00216-019-01611-w

Jin, 1980, Addition in drug combination (author's transl), Zhongguo Yao Li Xue Bao, 1, 70

Ding, 2019, Levistolide A synergistically enhances doxorubicin-induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway, Oncol Rep, 41, 1198

Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods, 25, 402, 10.1006/meth.2001.1262

Chou, 2006, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, 58, 621, 10.1124/pr.58.3.10

Yuan, 2015, The SIN1-PH domain connects mTORC2 to PI3K, Cancer Discov, 5, 1127, 10.1158/2159-8290.CD-15-1125

MondesireW, 2004, Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells, Clin Cancer Res, 10, 7031, 10.1158/1078-0432.CCR-04-0361

Shen, 2018, Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation, J Pineal Res, 64, 10.1111/jpi.12461

Hsu, 2018, Dual mTOR kinase inhibitor MLN0128 sensitizes HR+/HER2+ breast cancer patient-derived xenografts to trastuzumab or fulvestrant, Clin Cancer Res, 24, 395, 10.1158/1078-0432.CCR-17-1983

Zheng, 2016, Discoveries and controversies in BCL-2 protein-mediated apoptosis, FEBS J, 283, 2690, 10.1111/febs.13527

Ma, 2009, Molecular mechanisms of mTOR-mediated translational control, Nat Rev Mol Cell Biol, 10, 307, 10.1038/nrm2672

Bian, 2010, P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression, Biochem Biophys Res Commun, 398, 395, 10.1016/j.bbrc.2010.06.080

Yamnik, 2009, S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation, J Biol Chem, 284, 6361, 10.1074/jbc.M807532200

Qiu, 2016, The p70S6K specific inhibitor PF-4708671 impedes non-small cell lung cancer growth, PLoS One, 11, e0147185, 10.1371/journal.pone.0147185

Baba, 2009, Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma, Liver Int, 29, 399, 10.1111/j.1478-3231.2008.01798.x

Li, 2015, Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma, Surgery, 157, 570, 10.1016/j.surg.2014.10.014

No, 2011, Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer, Gynecol Oncol, 121, 8, 10.1016/j.ygyno.2010.12.364

Yoshida, 2013, Gene amplification of ribosomal protein S6 kinase-1 and −2 in gastric cancer, Anticancer Res, 33, 469

Grasso, 2014, Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation, Neoplasia, 16, 845, 10.1016/j.neo.2014.08.011

Xu, 2017, Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation, Oncotarget, 8, 30438, 10.18632/oncotarget.16737

Ji, 2018, Transcription activated p73-modulated cyclin D1 expression leads to doxorubicin resistance in gastric cancer, Exp Ther Med, 15, 1831

Gogolin, 2013, CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage, Cell Cycle, 12, 1091, 10.4161/cc.24091